{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:38:20Z","timestamp":1791581900419,"version":"4.3.4"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Darwinian clonal evolution provides a necessary framework for understanding tumour progression, yet emerging evidence shows that some cancers depart from a strictly gradualist tempo through episodic \"macroevolutionary\" leaps. We propose a unifying Burst-Drift-Control (BDC) model in which short-lived genomic reconfigurations (\"bursts\") that transiently alter heritable genomic states (\"reactive heredity\") precede longer intervals of constrained expansion, creating time-bounded vulnerabilities that clinicians may strategically steer (\"control\"). In this usage, the Drift component refers specifically to a drift-dominated or weak-selection interval after any initial post-burst sorting, not to the selective sweep itself. In the Burst phase, single catastrophic events, such as extrachromosomal DNA amplifications, chromothripsis, chromoplexy or whole-genome doubling, can generate major shifts in genotype and phenotype. These bursts produce new genetic configurations and can increase evolvability, for example when ecDNA circles permit oncogene dose tuning and non-Mendelian inheritance. During the drift-dominated interval, tumours may enter longer periods of constrained or near-neutral expansion in which spatial structure, clonal interference and weak or unresolved selection allow multiple lineages to persist, although the prevalence of such dynamics varies substantially by tumour type and treatment context. BDC does not assume that selective advantage is higher immediately after a burst than at later time points; later therapy or microenvironmental change can also impose strong selection. Finally, in the Control phase, if therapy is timed to exploit ecological dependencies and the fitness costs of resistance, cancer growth may be restrained as a stable, polyclonal \"oligopoly\" rather than progressing rapidly to an aggressive monoclonal takeover. We discuss supporting evidence, counterexamples and practical limitations, and argue that the main value of BDC lies in linking punctuated genome change to testable windows for evolutionary steering.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>The Burst-Drift-Control (BDC) cycle with reactive heredity. Macro-evolutionary bursts generate heritable variation, early post-burst sorting can include strong selection, and later drift-dominated or weak-selection intervals may create opportunities for adaptive control.<\/jats:p>","DOI":"10.1186\/s12943-026-02683-w","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T11:15:38Z","timestamp":1779448538000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Beyond Darwin: reactive heredity, burst-drift dynamics and eco\u2011evolutionary control of cancer"],"prefix":"10.1186","volume":"25","author":[{"given":"Laurine","family":"Lagache","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Salzet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Salzet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"2683_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1126\/science.959840","volume":"194","author":"PC Nowell","year":"1976","unstructured":"Nowell PC. The clonal evolution of tumor cell populations: acquired genetic lability permits stepwise selection of variant sublines and underlies tumor progression. Science. 1976;194:23\u20138.","journal-title":"Science"},{"key":"2683_CR2","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell"},{"key":"2683_CR3","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/nature10762","volume":"481","author":"M Greaves","year":"2012","unstructured":"Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012;481:306\u201313.","journal-title":"Nature"},{"key":"2683_CR4","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.cell.2013.03.021","volume":"153","author":"SC Baca","year":"2013","unstructured":"Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, Drier Y, et al. Punctuated evolution of prostate cancer genomes. Cell. 2013;153:666\u201377.","journal-title":"Cell"},{"key":"2683_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cell.2010.11.055","volume":"144","author":"PJ Stephens","year":"2011","unstructured":"Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ, et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell. 2011;144:27\u201340.","journal-title":"Cell"},{"key":"2683_CR6","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1101\/gad.229559.113","volume":"27","author":"C-Z Zhang","year":"2013","unstructured":"Zhang C-Z, Leibowitz ML, Pellman D. Chromothripsis and beyond: Rapid genome evolution from complex chromosomal rearrangements. Genes Dev. 2013;27:2513\u201330.","journal-title":"Genes Dev"},{"key":"2683_CR7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.cell.2011.12.013","volume":"148","author":"T Rausch","year":"2012","unstructured":"Rausch T, Jones DT, Zapatka M, St\u00fctz AM, Zichner T, Weischenfeldt J, et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell. 2012;148:59\u201371.","journal-title":"Cell"},{"key":"2683_CR8","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nature11284","volume":"488","author":"DT Jones","year":"2012","unstructured":"Jones DT, J\u00e4ger N, Kool M, Zichner T, Hutter B, Sultan M, et al. Dissecting the genomic complexity underlying medulloblastoma. Nature. 2012;488:100\u20135.","journal-title":"Nature"},{"key":"2683_CR9","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41588-018-0165-1","volume":"50","author":"CM Bielski","year":"2018","unstructured":"Bielski CM, Zehir A, Penson AV, Donoghue MT, Chatila W, Armenia J, et al. Genome doubling shapes the evolution and prognosis of advanced cancers. Nat Genet. 2018;50:1189\u201395.","journal-title":"Nat Genet"},{"key":"2683_CR10","doi-asserted-by":"publisher","first-page":"4918","DOI":"10.1158\/0008-5472.CAN-20-1920","volume":"80","author":"M Bolkestein","year":"2020","unstructured":"Bolkestein M, Wong JKL, Thewes V, K\u00f6rber V, Hlevnjak M, Elgaafary S, et al. Chromothripsis in human breast cancer. Can Res. 2020;80:4918\u201331. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-1920.","journal-title":"Can Res"},{"key":"2683_CR11","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/ng.3489","volume":"48","author":"MJ Williams","year":"2016","unstructured":"Williams MJ, Werner B, Barnes CP, Graham TA, Sottoriva A. Identification of neutral tumor evolution across cancer types. Nat Genet. 2016;48:238\u201344.","journal-title":"Nat Genet"},{"key":"2683_CR12","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/ng.3214","volume":"47","author":"A Sottoriva","year":"2015","unstructured":"Sottoriva A, Kang H, Ma Z, Graham TA, Salomon MP, Zhao J, et al. A Big Bang model of human colorectal tumor growth. Nat Genet. 2015;47:209\u201316.","journal-title":"Nat Genet"},{"key":"2683_CR13","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1038\/ng.3641","volume":"48","author":"R Gao","year":"2016","unstructured":"Gao R, Davis A, McDonald TO, Sei E, Shi X, Wang Y, et al. Punctuated copy number evolution and clonal stasis in triple-negative breast cancer. Nat Genet. 2016;48:1119\u201330.","journal-title":"Nat Genet"},{"key":"2683_CR14","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/s41588-018-0258-x","volume":"50","author":"M Tarabichi","year":"2018","unstructured":"Tarabichi M, Martincorena I, Gerstung M, Leroi AM, Markowetz F, Spellman PT, et al. Neutral tumor evolution? Nat Genet. 2018;50:1630\u20133. https:\/\/doi.org\/10.1038\/s41588-018-0258-x.","journal-title":"Nat Genet"},{"key":"2683_CR15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","volume":"141","author":"SV Sharma","year":"2010","unstructured":"Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010;141:69\u201380.","journal-title":"Cell"},{"key":"2683_CR16","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41568-019-0222-9","volume":"20","author":"M Fane","year":"2020","unstructured":"Fane M, Weeraratna AT. How the ageing microenvironment influences tumour progression. Nat Rev Cancer. 2020;20:89\u2013106.","journal-title":"Nat Rev Cancer"},{"key":"2683_CR17","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","volume":"371","author":"G Genovese","year":"2014","unstructured":"Genovese G, Kahler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371:2477\u201387.","journal-title":"N Engl J Med"},{"key":"2683_CR18","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","volume":"371","author":"S Jaiswal","year":"2014","unstructured":"Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371:2488\u201398.","journal-title":"N Engl J Med"},{"key":"2683_CR19","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1126\/science.aaa6806","volume":"348","author":"I Martincorena","year":"2015","unstructured":"Martincorena I, Roshan A, Gerstung M, Ellis P, Van Loo P, McLaren S, et al. Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science. 2015;348:880\u20136.","journal-title":"Science"},{"key":"2683_CR20","doi-asserted-by":"publisher","first-page":"eabc1048","DOI":"10.1126\/science.abc1048","volume":"373","author":"A Baggiolini","year":"2021","unstructured":"Baggiolini A, Callahan SJ, Montal E, Weiss JM, Trieu T, Tagore MM, et al. Developmental chromatin programs determine oncogenic competence in melanoma. Science. 2021;373:eabc1048. https:\/\/doi.org\/10.1126\/science.abc1048.","journal-title":"Science."},{"key":"2683_CR21","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/nrc2013","volume":"6","author":"LM Merlo","year":"2006","unstructured":"Merlo LM, Pepper JW, Reid BJ, Maley CC. Cancer as an evolutionary and ecological process. Nat Rev Cancer. 2006;6:924\u201335.","journal-title":"Nat Rev Cancer"},{"key":"2683_CR22","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/nature21356","volume":"543","author":"KM Turner","year":"2017","unstructured":"Turner KM, Deshpande V, Beyter D, Koga T, Rusert J, Lee C, et al. Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity. Nature. 2017;543:122\u20135.","journal-title":"Nature"},{"key":"2683_CR23","doi-asserted-by":"publisher","first-page":"e108389","DOI":"10.15252\/embj.2021108389","volume":"40","author":"R Vendramin","year":"2021","unstructured":"Vendramin R, Litchfield K, Swanton C. Cancer evolution: Darwin and beyond. EMBO J. 2021;40:e108389.","journal-title":"EMBO J"},{"key":"2683_CR24","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/j.cell.2013.02.023","volume":"152","author":"JO Korbel","year":"2013","unstructured":"Korbel JO, Campbell PJ. Criteria for inference of chromothripsis in cancer genomes. Cell. 2013;152:1226\u201336.","journal-title":"Cell"},{"key":"2683_CR25","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.ccr.2013.04.025","volume":"23","author":"MM Shen","year":"2013","unstructured":"Shen MM. Chromoplexy: a new category of complex rearrangements in the cancer genome. Cancer Cell. 2013;23:567\u20139. https:\/\/doi.org\/10.1016\/j.ccr.2013.04.025.","journal-title":"Cancer Cell"},{"key":"2683_CR26","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/j.cell.2015.11.054","volume":"163","author":"J Maciejowski","year":"2015","unstructured":"Maciejowski J, Li Y, Bosco N, Campbell PJ, De Lange T. Chromothripsis and kataegis induced by telomere crisis. Cell. 2015;163:1641\u201354.","journal-title":"Cell"},{"key":"2683_CR27","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nature23449","volume":"548","author":"KJ Mackenzie","year":"2017","unstructured":"Mackenzie KJ, Carroll P, Martin C-A, Murina O, Fluteau A, Simpson DJ, et al. cGAS surveillance of micronuclei links genome instability to innate immunity. Nature. 2017;548:461\u20135.","journal-title":"Nature"},{"key":"2683_CR28","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nature14493","volume":"522","author":"C-Z Zhang","year":"2015","unstructured":"Zhang C-Z, Spektor A, Cornils H, Francis JM, Jackson EK, Liu S, et al. Chromothripsis from DNA damage in micronuclei. Nature. 2015;522:179\u201384.","journal-title":"Nature"},{"key":"2683_CR29","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/s41586-023-05794-2","volume":"615","author":"RA Lambuta","year":"2023","unstructured":"Lambuta RA, Nanni L, Liu Y, Diaz-Miyar J, Iyer A, Tavernari D, et al. Whole-genome doubling drives oncogenic loss of chromatin segregation. Nature. 2023;615:925\u201333. https:\/\/doi.org\/10.1038\/s41586-023-05794-2.","journal-title":"Nature"},{"key":"2683_CR30","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/s41586-020-03133-3","volume":"590","author":"RJ Quinton","year":"2021","unstructured":"Quinton RJ, DiDomizio A, Vittoria MA, Kot\u00fdnkov\u00e1 K, Ticas CJ, Patel S, et al. Whole-genome doubling confers unique genetic vulnerabilities on tumour cells. Nature. 2021;590:492\u20137.","journal-title":"Nature"},{"key":"2683_CR31","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41568-019-0128-6","volume":"19","author":"RG Verhaak","year":"2019","unstructured":"Verhaak RG, Bafna V, Mischel PS. Extrachromosomal oncogene amplification in tumour pathogenesis and evolution. Nat Rev Cancer. 2019;19:283\u20138.","journal-title":"Nat Rev Cancer"},{"key":"2683_CR32","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/s41588-020-0678-2","volume":"52","author":"H Kim","year":"2020","unstructured":"Kim H, Nguyen N-P, Turner K, Wu S, Gujar AD, Luebeck J, et al. Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers. Nat Genet. 2020;52:891\u20137. https:\/\/doi.org\/10.1038\/s41588-020-0678-2.","journal-title":"Nat Genet"},{"key":"2683_CR33","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1038\/s41588-022-01177-x","volume":"54","author":"JT Lange","year":"2022","unstructured":"Lange JT, Rose JC, Chen CY, Pichugin Y, Xie L, Tang J, et al. The evolutionary dynamics of extrachromosomal DNA in human cancers. Nat Genet. 2022;54:1527\u201333. https:\/\/doi.org\/10.1038\/s41588-022-01177-x.","journal-title":"Nat Genet"},{"key":"2683_CR34","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41586-024-07861-8","volume":"635","author":"KL Hung","year":"2024","unstructured":"Hung KL, Jones MG, Wong IT-L, Curtis EJ, Lange JT, He BJ, et al. Coordinated inheritance of extrachromosomal DNAs in cancer cells. Nature. 2024;635:201\u20139. https:\/\/doi.org\/10.1038\/s41586-024-07861-8.","journal-title":"Nature"},{"key":"2683_CR35","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1158\/2159-8290.CD-21-1376","volume":"12","author":"E Yi","year":"2022","unstructured":"Yi E, Gujar AD, Guthrie M, Kim H, Zhao D, Johnson KC, et al. Live-cell imaging shows uneven segregation of extrachromosomal DNA elements and transcriptionally active extrachromosomal DNA hubs in cancer. Cancer Discov. 2022;12:468\u201383.","journal-title":"Cancer Discov"},{"key":"2683_CR36","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1158\/2159-8290.CD-24-1555","volume":"15","author":"I Noorani","year":"2025","unstructured":"Noorani I, Haughey M, Luebeck J, Rowan A, Gr\u00f6nroos E, Terenzi F, et al. Extrachromosomal DNA-driven oncogene spatial heterogeneity and evolution in glioblastoma. Cancer Discov. 2025;15:2078\u201395. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-1555.","journal-title":"Cancer Discov"},{"key":"2683_CR37","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1126\/science.1241328","volume":"343","author":"DA Nathanson","year":"2014","unstructured":"Nathanson DA, Gini B, Mottahedeh J, Visnyei K, Koga T, Gomez G, et al. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science. 2014;343:72\u20136.","journal-title":"Science"},{"key":"2683_CR38","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1056\/NEJMoa1616288","volume":"376","author":"M Jamal-Hanjani","year":"2017","unstructured":"Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TB, Veeriah S, et al. Tracking the evolution of non\u2013small-cell lung cancer. N Engl J Med. 2017;376:2109\u201321.","journal-title":"N Engl J Med"},{"key":"2683_CR39","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nature09807","volume":"472","author":"N Navin","year":"2011","unstructured":"Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, et al. Tumour evolution inferred by single-cell sequencing. Nature. 2011;472:90\u20134.","journal-title":"Nature"},{"key":"2683_CR40","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.ccell.2023.01.010","volume":"41","author":"O Elhanani","year":"2023","unstructured":"Elhanani O, Ben-Uri R, Keren L. Spatial profiling technologies illuminate the tumor microenvironment. Cancer Cell. 2023;41:404\u201320. https:\/\/doi.org\/10.1016\/j.ccell.2023.01.010.","journal-title":"Cancer Cell"},{"key":"2683_CR41","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nature14971","volume":"525","author":"B Waclaw","year":"2015","unstructured":"Waclaw B, Bozic I, Pittman ME, Hruban RH, Vogelstein B, Nowak MA. A spatial model predicts that dispersal and cell turnover limit intratumour heterogeneity. Nature. 2015;525:261\u20134.","journal-title":"Nature"},{"key":"2683_CR42","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","volume":"168","author":"N McGranahan","year":"2017","unstructured":"McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: Past, present, and the future. Cell. 2017;168:613\u201328.","journal-title":"Cell"},{"key":"2683_CR43","doi-asserted-by":"publisher","first-page":"283ra254","DOI":"10.1126\/scitranslmed.aaa1408","volume":"7","author":"N McGranahan","year":"2015","unstructured":"McGranahan N, Favero F, De Bruin EC, Birkbak NJ, Szallasi Z, Swanton C. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Sci Transl Med. 2015;7:283ra254-283ra254.","journal-title":"Sci Transl Med."},{"key":"2683_CR44","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1126\/science.1239947","volume":"343","author":"BE Johnson","year":"2014","unstructured":"Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science. 2014;343:189\u201393.","journal-title":"Science"},{"key":"2683_CR45","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1101\/gr.180612.114","volume":"25","author":"H Kim","year":"2015","unstructured":"Kim H, Zheng S, Amini SS, Virk SM, Mikkelsen T, Brat DJ, et al. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome Res. 2015;25:316\u201327. https:\/\/doi.org\/10.1101\/gr.180612.114.","journal-title":"Genome Res"},{"key":"2683_CR46","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1093\/neuonc\/noae214","volume":"27","author":"C-HG Lucas","year":"2025","unstructured":"Lucas C-HG, Al-Adli NN, Young JS, Gupta R, Morshed RA, Wu J, et al. Longitudinal multimodal profiling of IDH-wildtype glioblastoma reveals the molecular evolution and cellular phenotypes underlying prognostically different treatment responses. Neuro Oncol. 2025;27:89\u2013105. https:\/\/doi.org\/10.1093\/neuonc\/noae214.","journal-title":"Neuro Oncol"},{"key":"2683_CR47","doi-asserted-by":"publisher","first-page":"e93019","DOI":"10.7554\/eLife.93019","volume":"13","author":"K Nuno","year":"2024","unstructured":"Nuno K, Azizi A, Koehnke T, Lareau C, Ediriwickrema A, Corces MR, et al. Convergent epigenetic evolution drives relapse in acute myeloid leukemia. Elife. 2024;13:e93019. https:\/\/doi.org\/10.7554\/eLife.93019.","journal-title":"Elife."},{"key":"2683_CR48","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/nm.4040","volume":"22","author":"AN Hata","year":"2016","unstructured":"Hata AN, Niederst MJ, Archibald HL, Gomez-Caraballo M, Siddiqui FM, Mulvey HE, et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat Med. 2016;22:262\u20139.","journal-title":"Nat Med."},{"key":"2683_CR49","doi-asserted-by":"publisher","first-page":"802177","DOI":"10.3389\/fonc.2021.802177","volume":"11","author":"N Hajjaji","year":"2022","unstructured":"Hajjaji N, Aboulouard S, Cardon T, Bertin D, Robin YM, Fournier I, et al. Path to clonal theranostics in luminal breast cancers. Front Oncol. 2022;11:802177. https:\/\/doi.org\/10.3389\/fonc.2021.802177.","journal-title":"Front Oncol"},{"key":"2683_CR50","doi-asserted-by":"publisher","first-page":"100891","DOI":"10.1016\/j.mcpro.2024.100891","volume":"24","author":"L Lagache","year":"2025","unstructured":"Lagache L, Zirem Y, Le Rhun E, Fournier I, Salzet M. Predicting protein pathways associated to tumor heterogeneity by correlating spatial lipidomics and proteomics: the dry proteomic concept. Mol Cell Proteomics. 2025;24:100891. https:\/\/doi.org\/10.1016\/j.mcpro.2024.100891.","journal-title":"Mol Cell Proteomics"},{"key":"2683_CR51","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/nature16478","volume":"529","author":"AS Morrissy","year":"2016","unstructured":"Morrissy AS, Garzia L, Shih DJ, Zuyderduyn S, Huang X, Skowron P, et al. Divergent clonal selection dominates medulloblastoma at recurrence. Nature. 2016;529:351\u20137.","journal-title":"Nature"},{"key":"2683_CR52","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1056\/NEJMoa044238","volume":"352","author":"S Kobayashi","year":"2005","unstructured":"Kobayashi S, Boggon TJ, Dayaram T, J\u00e4nne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non\u2013small-cell lung cancer to gefitinib. N Engl J Med. 2005;352:786\u201392.","journal-title":"N Engl J Med"},{"key":"2683_CR53","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nature11219","volume":"486","author":"LA Diaz Jr","year":"2012","unstructured":"Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012;486:537\u201340.","journal-title":"Nature"},{"key":"2683_CR54","doi-asserted-by":"publisher","first-page":"75ra26","DOI":"10.1126\/scitranslmed.3002003","volume":"3","author":"LV Sequist","year":"2011","unstructured":"Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3:75ra26-75ra26.","journal-title":"Sci Transl Med"},{"key":"2683_CR55","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1158\/0008-5472.CAN-06-0127","volume":"66","author":"C Hunter","year":"2006","unstructured":"Hunter C, Smith R, Cahill DP, Stephens P, Stevens C, Teague J, et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res. 2006;66:3987\u201391.","journal-title":"Cancer Res"},{"key":"2683_CR56","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1038\/s41588-019-0525-5","volume":"51","author":"O Pich","year":"2019","unstructured":"Pich O, Mui\u00f1os F, Lolkema MP, Steeghs N, Gonzalez-Perez A, Lopez-Bigas N. The mutational footprints of cancer therapies. Nat Genet. 2019;51:1732\u201340.","journal-title":"Nat Genet"},{"key":"2683_CR57","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nature22794","volume":"546","author":"SM Shaffer","year":"2017","unstructured":"Shaffer SM, Dunagin MC, Torborg SR, Torre EA, Emert B, Krepler C, et al. Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. Nature. 2017;546:431\u20135. https:\/\/doi.org\/10.1038\/nature22794.","journal-title":"Nature"},{"key":"2683_CR58","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nature24297","volume":"551","author":"MJ Hangauer","year":"2017","unstructured":"Hangauer MJ, Viswanathan VS, Ryan MJ, Bole D, Eaton JK, Matov A, et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature. 2017;551:247\u201350. https:\/\/doi.org\/10.1038\/nature24297.","journal-title":"Nature"},{"key":"2683_CR59","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","volume":"21","author":"D Hanahan","year":"2012","unstructured":"Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21:309\u201322.","journal-title":"Cancer Cell"},{"key":"2683_CR60","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1083\/jcb.201102147","volume":"196","author":"P Lu","year":"2012","unstructured":"Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol. 2012;196:395\u2013406. https:\/\/doi.org\/10.1083\/jcb.201102147.","journal-title":"J Cell Biol"},{"key":"2683_CR61","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nature11183","volume":"487","author":"R Straussman","year":"2012","unstructured":"Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012;487:500\u20134.","journal-title":"Nature"},{"key":"2683_CR62","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41586-019-1876-x","volume":"578","author":"HW Jackson","year":"2020","unstructured":"Jackson HW, Fischer JR, Zanotelli VR, Ali HR, Mechera R, Soysal SD, et al. The single-cell pathology landscape of breast cancer. Nature. 2020;578:615\u201320.","journal-title":"Nature"},{"key":"2683_CR63","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41568-025-00803-0","volume":"25","author":"KL Simpson","year":"2025","unstructured":"Simpson KL, Rothwell DG, Blackhall F, Dive C. Challenges of small cell lung cancer heterogeneity and phenotypic plasticity. Nat Rev Cancer. 2025;25:447\u201362. https:\/\/doi.org\/10.1038\/s41568-025-00803-0.","journal-title":"Nat Rev Cancer"},{"key":"2683_CR64","unstructured":"Yu C, Geuenich MJ, Ge S, Jang GH, Ju TT, Zhang A, O\u2019Kane GM, Notta F, Campbell KR. Decoding multicellular niche formation in the tumour microenvironment from nonspatial single-cell expression data. bioRxiv. 2024.2008. 2021.608956."},{"key":"2683_CR65","doi-asserted-by":"publisher","first-page":"327ra324","DOI":"10.1126\/scitranslmed.aad7842","volume":"8","author":"PM Enriquez-Navas","year":"2016","unstructured":"Enriquez-Navas PM, Kam Y, Das T, Hassan S, Silva A, Foroutan P, et al. Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer. Sci Transl Med. 2016;8:327ra324-327ra324.","journal-title":"Sci Transl Med."},{"key":"2683_CR66","doi-asserted-by":"publisher","first-page":"e76284","DOI":"10.7554\/eLife.76284","volume":"11","author":"J Zhang","year":"2022","unstructured":"Zhang J, Cunningham J, Brown J, Gatenby R. Evolution-based mathematical models significantly prolong response to abiraterone in metastatic castrate-resistant prostate cancer and identify strategies to further improve outcomes. Elife. 2022;11:e76284. https:\/\/doi.org\/10.7554\/eLife.76284.","journal-title":"Elife"},{"key":"2683_CR67","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-19-2669","volume":"80","author":"J West","year":"2020","unstructured":"West J, You L, Zhang J, Gatenby RA, Brown JS, Newton PK, et al. Towards multidrug adaptive therapy. Cancer Res. 2020;80:1578\u201389.","journal-title":"Cancer Res"},{"key":"2683_CR68","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/459508a","volume":"459","author":"RA Gatenby","year":"2009","unstructured":"Gatenby RA. A change of strategy in the war on cancer. Nature. 2009;459:508\u20139.","journal-title":"Nature"},{"key":"2683_CR69","doi-asserted-by":"publisher","first-page":"e2007066","DOI":"10.1371\/journal.pbio.2007066","volume":"16","author":"F Thomas","year":"2018","unstructured":"Thomas F, Donnadieu E, Charriere GM, Jacqueline C, Tasiemski A, Pujol P, et al. Is adaptive therapy natural? PLoS Biol. 2018;16:e2007066.","journal-title":"PLoS Biol"},{"key":"2683_CR70","doi-asserted-by":"publisher","first-page":"a040972","DOI":"10.1101\/cshperspect.a040972","volume":"10","author":"RA Gatenby","year":"2020","unstructured":"Gatenby RA, Brown JS. The evolution and ecology of resistance in cancer therapy. Cold Spring Harb Perspect Med. 2020;10:a040972.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2683_CR71","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/nm.3854","volume":"21","author":"KS Thress","year":"2015","unstructured":"Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015;21:560\u20132. https:\/\/doi.org\/10.1038\/nm.3854.","journal-title":"Nat Med"},{"key":"2683_CR72","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1158\/1078-0432.CCR-13-2482","volume":"20","author":"GR Oxnard","year":"2014","unstructured":"Oxnard GR, Paweletz CP, Kuang Y, Mach SL, O\u2019Connell A, Messineo MM, et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res. 2014;20:1698\u2013705. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2482.","journal-title":"Clin Cancer Res"},{"key":"2683_CR73","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature22364","volume":"545","author":"C Abbosh","year":"2017","unstructured":"Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545:446\u201351.","journal-title":"Nature"},{"key":"2683_CR74","doi-asserted-by":"publisher","first-page":"13474","DOI":"10.1073\/pnas.0606053103","volume":"103","author":"R Axelrod","year":"2006","unstructured":"Axelrod R, Axelrod DE, Pienta KJ. Evolution of cooperation among tumor cells. Proc Natl Acad Sci U S A. 2006;103:13474\u20139. https:\/\/doi.org\/10.1073\/pnas.0606053103.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2683_CR75","doi-asserted-by":"crossref","unstructured":"Simpson KL, Rothwell DG, Blackhall F, Dive C. Challenges of small cell lung cancer heterogeneity and phenotypic plasticity. Nat Re Cancer, 2025; 1\u201316.","DOI":"10.1038\/s41568-025-00803-0"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02683-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02683-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02683-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T09:02:48Z","timestamp":1784192568000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-026-02683-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2683"],"URL":"https:\/\/doi.org\/10.1186\/s12943-026-02683-w","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"7 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This Perspective did not involve new studies in human participants or animals and did not use identifiable patient data; therefore, ethics approval and consent were not required.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"177"}}